Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.4350
+0.0050 (1.16%)
Aug 27, 2026, 1:42 PM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 1.79 billion as of August 27, 2026. Its market cap has decreased by -43.51% in one year.
Market Cap
1.79B
Enterprise Value
2.04B
Revenue
718.98M
Ranking
n/a
PE Ratio
39.09
Stock Price
0.44
ChartMarket Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 1.79B, a decrease of -64.05%. That is a compound annual growth rate of -13.17%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 27, 2026 | 1.79B | -13.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| TYK Medicines | 2.51B |
| Frontage Holdings | 2.44B |
| Shandong Boan Biotechnology | 2.40B |
| PegBio | 2.30B |
| AIM Vaccine | 1.98B |
| Guangzhou Innogen Pharmaceutical Group | 1.84B |
| HighTide Therapeutics | 1.75B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.60B |